Mogam Institute for Biomedical Research Selected as Research Institution for K-AI New Drug Development Project

On November 5, the Mogam Institute for Biomedical Research announced that it had been selected as a participating research institution for the "K-AI New Drug Development Preclinical-Clinical Model Development Project," which is overseen by the Ministry of Health and Welfare.

This "K-AI New Drug Development Preclinical-Clinical Model Development Project" is led by the Ministry of Health and Welfare and aims to establish and develop a clinical trial design and support platform for AI-based new drug development using innovative artificial intelligence technology. The project seeks to build a domestic AI-driven, full-cycle new drug development ecosystem by accelerating the linkage and transition between the preclinical and clinical stages.

For this project, the Mogam Institute will lead the development of "Translational Research AI Software." This research focuses on developing AI technology that connects various experimental data generated at the preclinical stage with early clinical data to support the transition to the clinical phase in new drug development. The institute will be responsible for: ▲ developing AI models to predict drug responsiveness, toxicity, and dosage by linking preclinical and clinical data; ▲ creating AI inference agents that predict clinical transition success rates based on drug prediction models; and ▲ enhancing performance through empirical validation using federated learning.

Through this project, the Mogam Institute plans to present a concrete model of translational research software, demonstrating how AI technology can function as a practical AI assistant that goes beyond simple analytical tools to actively promote the transition to the clinical stage.

Director Shin Hyunjin commented, "Through our translational research AI software, the Mogam Institute for Biomedical Research is working to bridge the data gap between preclinical and clinical stages and to develop foundational technology that enables AI to independently assess clinical transition potential. This research will mark a significant turning point in AI-driven drug development, and the Mogam Institute will continue to contribute to enhancing the innovative competitiveness of Korea's pharmaceutical and biotechnology industries."